A pooled analysis of two trials suggests zuranolone effects in Japanese depression subgroups were consistent, with sleep symptoms contributing most to early treatment differences. The readout supports the idea that the drug’s earliest clinical separation may be driven by improvements in sleep domains. Meanwhile, a systematic review found that baloxavir post-exposure prophylaxis showed a larger estimated association with reduced household influenza than treatment of infected index patients. The result strengthens the case for prophylaxis-focused strategies to curb transmission in close-contact settings. Together, the updates show both psychiatric and infectious disease developers leaning on cross-subgroup consistency and real-world transmission logic to justify clinical and regulatory decision-making.